Literature DB >> 11549872

Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents.

M B Ranke1, R Schweizer, M W Elmlinger, K Weber, G Binder, C P Schwarze, H A Wollmann.   

Abstract

BACKGROUND: Little information is available on the relevance of parameters representing the insulin-like growth factor (IGF) system with regard to growth hormone (GH) treatment during childhood. In adults, high IGF-I levels were found to be associated with side effects and long-term risks. AIM/
METHOD: Our aim was to monitor the serum levels of IGF-I, IGF-binding protein (IGFBP) 3, and IGFBP-2 during long-term GH treatment of 156 patients with GH deficiency (GHD) and of 153 non-GHD patients. We determined the extent to which the IGF parameters exceed the normal ranges and identified those parameters which are predictive of 1st-year growth.
RESULTS: In prepubertal GHD children, the levels of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 exceeded the 95th centile of the reference values for this age group in 2.3, 0.3, and 7.9% of the cases, respectively, whereas in prepubertal non-GHD children, the same parameters exceeded the 95th reference centile in 20.1, 3.5, and 32.2%, respectively. In pubertal GHD children IGF-I, IGFBP-3, and IGF-I/IGFBP-3 levels exceeded the 95th reference centile in 11.1, 1.5, and 15.4%, respectively. In pubertal non-GHD children, these levels also exceeded the 95th centile in 26.7, 7.0, and 41.4%, respectively. In both GHD and non-GHD groups, however, some patients had IGF parameters which were below the reference values. Our analysis showed that, in both groups, in addition to maximum GH, all IGF parameters (IGF-I, IGFBP-3, IGF-I/IGFBP-3 ratio, IGFBP-2 or derivatives) significantly extend the scope of a calculated model for predicting 1st-year height velocity.
CONCLUSION: For reasons of safety and optimization of GH therapy, it is essential to follow up IGF-I, IGFBP-3, and IGFBP-2 levels regularly during childhood. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549872     DOI: 10.1159/000049982

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  11 in total

1.  Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort.

Authors:  Andreea Nissenkorn; Yael Levy-Shraga; Yonit Banet-Levi; Avishay Lahad; Ifat Sarouk; Dalit Modan-Moses
Journal:  Pediatr Res       Date:  2016-02-18       Impact factor: 3.756

Review 2.  Advances in differential diagnosis and management of growth hormone deficiency in children.

Authors:  Camille Hage; Hoong-Wei Gan; Anastasia Ibba; Giuseppa Patti; Mehul Dattani; Sandro Loche; Mohamad Maghnie; Roberto Salvatori
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

3.  Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38].

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-08

4.  Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients.

Authors:  Zeynep Sıklar; Gönül Öcal; Merih Berberoğlu; Pelin Bilir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-08-05

5.  Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain.

Authors:  Elena Lundberg; Berit Kriström; Bjorn Jonsson; Kerstin Albertsson-Wikland
Journal:  BMC Endocr Disord       Date:  2015-12-18       Impact factor: 2.763

6.  Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency.

Authors:  Sheila Perez-Colon; Oksana Lazareva; Radhika Purushothaman; Shahid Malik; Svetlana Ten; Amrit Bhangoo
Journal:  Int J Endocrinol Metab       Date:  2018-05-21

7.  Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1.

Authors:  João Soares Felício; Luísa Corrêa Janaú; Marcelle Alves Moraes; Nathalie Abdallah Zahalan; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Norberto Jorge Kzan de Souza Neto; Isabela Imbelloni Farias de Franco; Loyane Tamyres Costa Leitão; Lilian de Souza d'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Angélica Leite de Alcântara; Ana Carolina Contente Braga de Souza; Wanderson Maia da Silva; Márcia Costa Dos Santos; Natércia Neves Marques de Queiroz; Lorena Vilhena de Moraes; Antônio Bentes de Figueiredo; Ana Luiza Prieto Farinassi; Luciana Marques da Costa Farias; Danielle Dias da Silva; Karem Miléo Felício; João Felício Abrahão Neto
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-19       Impact factor: 5.555

8.  Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood.

Authors:  Masanobu Fujimoto; Jane C Khoury; Philip R Khoury; Bhanu Kalra; Ajay Kumar; Patrick Sluss; Claus Oxvig; Vivian Hwa; Andrew Dauber
Journal:  Eur J Endocrinol       Date:  2020-03       Impact factor: 6.664

9.  Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

Authors:  A Stevens; P Clayton; L Tatò; H W Yoo; M D Rodriguez-Arnao; J Skorodok; G R Ambler; M Zignani; J Zieschang; G Della Corte; B Destenaves; A Champigneulle; J Raelson; P Chatelain
Journal:  Pharmacogenomics J       Date:  2013-04-09       Impact factor: 3.550

10.  Associations between Psychological Problems and Quality of Life in Pediatric Short Stature from Patients' and Parents' Perspectives.

Authors:  Julia Hannah Quitmann; Monika Bullinger; Rachel Sommer; Anja Christine Rohenkohl; Neuza Maria Bernardino Da Silva
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.